Click here to view the slides referenced in the webcast.
A Critical Assessment of Valve Performance and Outcomes in Patients at Low Risk for Surgery
See what leading interventionalists have to say about hot topics in TAVR today.
- Patients Enrolled in the Evolut™ Low Risk Trial - the Critical Role of the Heart Team
Gregory P. Fontana, Michael Deeb, and John Forrest
- The Clinical Impact of Bioprosthetic Valve Performance After Surgery and TAVR
Daniel O’Hair, Renuka Jain, and Hemal Gada
- High-Level Results of the Evolut™ Low Risk Randomized Clinical Trial
Daniel O’Hair, Michael Reardon, and John Forrest
- Understanding Early and Late Mortality in Low Risk Randomized Trials
Gregory P. Fontana, Michael Deeb, and Michael Reardon
- Lifetime Management Considerations in Low Risk Patients
Gregory P. Fontana, Renuka Jain, Hemal Gada, and Michael Deeb
| This program is supported by: | Medtronic |
 |
Michael Deeb, MD University of Michigan Ann Arbor, MI |
 |
Gregory P. Fontana, MD Los Robles Hospital and Medical Center Thousand Oaks, CA |
 |
John Forrest, MD Yale New Haven Hospital New Haven, CT |
 |
Hemal Gada, MD Heart and Vascular Institute UPMC Pinnacle Harrisburg, PA |
 |
Renuka Jain, MD Aurora St. Luke's Medical Center Milwaukee, WI |
 |
Daniel O'Hair, MD Boulder Heart, Boulder Community Health Boulder, CO |
 |
Michael Reardon, MD Houston Methodist Debakey Heart & Vascular Center Houston, TX |
| This program is sponsored by: | Medtronic |